Skip to main content

Featured

Wall Street Sinks as Tariff Jitters and AI Volatility Rattle Investors

U.S. stocks tumbled in a broad sell‑off today, with the Dow Jones Industrial Average plunging roughly 800 points as renewed tariff concerns and a wave of AI‑related volatility shook market confidence. The S&P 500 and Nasdaq also slid sharply, extending a week of choppy trading driven by political uncertainty and rapid shifts in tech sentiment. Investors reacted to escalating fears that new tariff measures proposed by President Trump could disrupt global supply chains and pressure corporate earnings. Tech stocks—already sensitive to policy shifts—were hit particularly hard as traders unwound positions tied to what analysts have dubbed the “AI scare trade,” a fast‑moving rotation away from high‑growth names. Market strategists noted that the combination of geopolitical tension, policy ambiguity, and stretched valuations created a perfect storm for a sharp pullback. Still, some analysts argue that the downturn reflects a recalibration rather than a fundamental shift, pointing out t...
Post a Comment
Read more

article

Labels

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine


Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

This is the second vaccine targeting XBB.1.5 that will be available in this country.

Earlier this month, Health Canada authorized Moderna's updated mRNA vaccine.

Both Pfizer and Moderna's shots are one-dose vaccines for people five years of age and older.

Three shots of the Pfizer vaccine is recommended for children between six months and four years of age who have not received their primary series of a COVID-19 vaccine.

Health Canada says it is currently reviewing an updated non-mRNA vaccine from Novavax.

Novavax’s vaccine has been submitted for consideration for people age 12 years and older.

Labels:

Comments

Post a Comment